Regional Patterns and Temporal Trends of Pfdhfr and Pfdhps Markers of Antifolate Resistance in Plasmodium falciparum in East and West Africa, 2010-2025: A Systematic Review.

Acta TropJul 12, 2026 (epub)
Clinical ResearchInfectious Diseases

Loise Ndung'u, Brenda Muriithi, Stephen Gitahi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed regional patterns and trends of Pfdhfr and Pfdhps mutations linked to sulfadoxine-pyrimethamine resistance in Plasmodium falciparum across East and West Africa from 2010 to 2025. The study found a very high prevalence of specific mutations in East Africa, while West Africa exhibited a different mutation profile. Notably, K540E remained low in West Africa.

Key findings

  • East Africa showed very high prevalence of Pfdhfr N51I, C59R, and S108N mutations.
  • In West Africa, K540E remained low, while alternative Pfdhps variants were more common.
  • Temporal analyses indicated persistently high prevalence of major markers in East Africa.
  • West Africa maintained moderate to high levels of Pfdhfr mutations over time.

Why it matters

Understanding regional differences in antifolate resistance markers is crucial for effective malaria treatment strategies. This knowledge can inform targeted surveillance and guide public health interventions to combat malaria in affected regions.

Source

PubMed · PMID 42437651

Published in Acta Trop. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.